EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

Catana Allert, Carsten Müller-Tidow, Maximilian Felix Blank iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34684 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Catana Allert und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, José Carreras Leukämie-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem CellsLeukemia, Myeloid, AcuteHumansBone MarrowSignal TransductionCell CommunicationTumor Microenvironment

Stichwörter der Autor:innen

cell adhesion-mediated drug resistanceniche related therapiessoluble factor-mediated drug resistance

Autor:innen und Institutionen

  • Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • University of Heidelberg Medical Faculty, Heidelberg, Germany.
  • Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Division Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Maximilian Felix Blank

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe
  • José Carreras Leukämie-Stiftung
  • Wilhelm-Sander-Stiftung

Zitieren

APA

Allert, C., Müller-Tidow, C., & Blank, M. F. (2024). The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. International Journal of Cancer. https://doi.org/10.1002/ijc.34684

Vancouver

Allert C, Müller-Tidow C, Blank MF. The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia. International Journal of Cancer. 2024. doi:10.1002/ijc.34684

BibTeX
@article{Allert2024,
  author = {Allert, Catana and Müller-Tidow, Carsten and Blank, Maximilian Felix},
  title = {The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34684}
}
Kostenlos starten →